Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARRx and enzalutamide in metastatic castration-resistant prostate cancer
NCT03300505Phase 1Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2019
- Primary completion
- Jan 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD5312 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Dose-limiting Toxicity at 21 days and Best PSA Response at 3.5 years. Started May 2019; status: terminated.
02
Drugs
AZD5312
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03300505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03300505.